Sun Pharmaceutical Industries rises as its arm incorporates wholly-owned subsidiary
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Sun Pharmaceutical Industries is currently trading at Rs. 1468.50, up by 4.60 points or 0.31% from its previous closing of Rs. 1463.90 on the BSE.
The scrip opened at Rs. 1463.50 and has touched a high and low of Rs. 1470.40 and Rs. 1450.00 respectively. So far 13171 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1,472.00 on 06-Feb-2024 and a 52 week low of Rs. 922.55 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1472.00 and Rs. 1367.75 respectively. The current market cap of the company is Rs. 351958.45 crore.
The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.59% and 8.92% respectively.
Sun Pharmaceutical Industries’ subsidiary -- Taro Pharmaceutical Industries has incorporated wholly-owned subsidiary company with the name ‘Taro Pharma Corporation, Inc.’ (USA) on February 5, 2024. Taro Pharma Corporation is set up as an entity separate from Alchemee LLC, a subsidiary of Taro Israel, to help Alchemee LLC with selling its Proactiv skincare products on e-commerce marketplace in USA.
Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.
